NanoVation Therapeutics develops scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations customized for specific targets, payloads, and routes of administration. Their long-circulating LNP (lcLNP) platform enhances potency, safety, and stability for nucleic acid delivery beyond the liver. The company provides a comprehensive delivery toolbox, including novel lipid design and LNP compositions, to support partners in advancing next-generation genetic medicines.
Funding
Funding not disclosed
Founders
Product
Problem
Current nucleic acid delivery methods face challenges in safely and efficiently targeting tissues beyond the liver, limiting the therapeutic potential of genetic medicines. Existing lipid nanoparticle (LNP) technologies often lack the specificity and stability required for effective extrahepatic delivery.
Solution
NanoVation Therapeutics develops customized, scalable lipid nanoparticle (LNP) formulations for targeted nucleic acid delivery to a variety of tissues. Their next-generation platform technologies overcome the limitations of existing approaches, enabling the development of genetic medicines for diseases beyond the liver. NanoVation's long-circulating LNP (lcLNP™) technology demonstrates improved potency, safety, and stability in preclinical studies. The company offers comprehensive solutions spanning novel lipid design, RNA modifications, and LNP compositions, empowering partners to rapidly develop their genetic medicines.
Target Audience
The primary customers are pharmaceutical and biotechnology companies developing genetic medicines, particularly those focused on extrahepatic delivery and novel LNP formulations.
Features
- Scalable, nucleic acid-agnostic LNP formulations customized for specific targets, payloads, and routes of administration
- Extensive library of novel lipids and LNP compositions
- Long-circulating LNP (lcLNP™) technology for improved potency, safety, and stability
- Toolbox for LNP-based genetic medicine development, including novel lipid design, RNA modifications, and LNP compositions
- Expertise in mRNA synthesis and LNP formulation, through to preclinical trials and delivery optimization